In colorectal cancer, activation of PERK has been reported to increase sensitivity to paclitaxel, while the combination of 5-fluorouracil and withaferin A promotes apoptosis via the PERK axis, overcoming chemoresistance190. Here, EIF2AK3 is linked to colorectal cancer.